Can I switch directly from 20 mg of lurasidone (Latuda) to brexpiprazole (Rexulti) because of akathisia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Direct Switch from Latuda 20mg to Rexulti for Akathisia

Yes, you can switch directly from Latuda 20mg to Rexulti (brexpiprazole) for akathisia, using a gradual cross-titration approach rather than an abrupt switch. This strategy addresses the akathisia while maintaining antipsychotic coverage and minimizing withdrawal or rebound symptoms.

Rationale for Switching

Akathisia is a well-documented adverse effect of lurasidone (Latuda), with FDA labeling showing akathisia rates of 5.6% at 20mg/day 11. The evidence demonstrates that:

  • Lurasidone has a higher akathisia burden compared to brexpiprazole. Meta-analysis data shows lurasidone has an akathisia incidence of 12.7% overall, while brexpiprazole shows 10.0% 2
  • Brexpiprazole may be better tolerated in patients who have failed switches to other dopamine partial agonists, with retrospective data suggesting safer switching profiles compared to aripiprazole 3
  • Both medications are second-generation antipsychotics but have different pharmacodynamic profiles, making this a reasonable switch per guideline recommendations 4

Switching Strategy

Use gradual cross-titration as recommended by the 2025 INTEGRATE guidelines 4:

  1. Start brexpiprazole at 1mg/day while continuing Latuda 20mg
  2. After 3-4 days, increase brexpiprazole to 2mg/day
  3. Simultaneously begin tapering Latuda by 50% (to 10mg/day)
  4. After another 3-4 days, increase brexpiprazole to target dose (2-4mg/day) and discontinue Latuda
  5. Total cross-titration period: 7-10 days

This gradual approach is informed by:

  • The half-life and receptor profiles of each medication 4
  • Lurasidone's relatively short half-life requiring food administration
  • Brexpiprazole's partial dopamine agonist properties requiring gradual introduction

Important Caveats

Monitor for akathisia persistence: While brexpiprazole has a lower akathisia rate than lurasidone in meta-analyses 2, it still carries akathisia risk (RR 1.72 vs placebo) 5. The 2mg dose of brexpiprazole shows less akathisia risk than 4mg 5.

Consider adjunctive management during transition:

  • Beta-blockers (propranolol 30-90mg/day) are first-line adjuncts for akathisia 6
  • Benzodiazepines can provide temporary relief during the cross-titration
  • These can be tapered once the switch is complete and akathisia resolves

Special considerations:

  • If you're treating schizophrenia with treatment-resistant features, switching success rates may be lower 3
  • Brexpiprazole is FDA-approved for schizophrenia and MDD augmentation, so ensure the indication aligns
  • Both medications require different dosing considerations (Latuda with food ≥350 calories; brexpiprazole without food restrictions)

Expected Outcomes

Akathisia should improve within 1-2 weeks of completing the switch. If akathisia persists at the same severity after switching to brexpiprazole 2mg/day, this suggests either:

  • The akathisia may be related to class effects rather than medication-specific
  • Consider dose reduction of brexpiprazole or addition of adjunctive treatments 6
  • Re-evaluate if this represents tardive akathisia rather than acute medication-induced akathisia

Do not switch abruptly - the guideline explicitly recommends against abrupt switches, particularly when moving between different pharmacodynamic profiles 4. The gradual cross-titration minimizes risk of symptom exacerbation or withdrawal effects.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.